Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.7
16.24
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Other Current Liabilities
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
Other Current Liabilities
¥258.8m
|
CAGR 3-Years
6%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Current Liabilities
¥530.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Current Liabilities
¥299.9m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
10%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Current Liabilities
¥3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Current Liabilities
¥3.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
13%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Current Liabilities
¥101.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Glance View
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. is a holding company that engages in the research, development, manufacture and sale of biochemical pharmaceutical products. The company is headquartered in Nanjing, Jiangsu and currently employs 1,006 full-time employees. The company went IPO on 2017-07-19. The firm's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The firm mainly exports its products to the United States and European countries.
See Also
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Current Liabilities?
Other Current Liabilities
258.8m
CNY
Based on the financial report for Sep 30, 2024, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Current Liabilities amounts to 258.8m CNY.
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
17%
Over the last year, the Other Current Liabilities growth was 23%. The average annual Other Current Liabilities growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been 6% over the past three years , 17% over the past five years .
You don't have any saved screeners yet
